Simplify Asset Management Inc. Buys 53,531 Shares of Viridian Therapeutics, Inc. $VRDN

Simplify Asset Management Inc. increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 107.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,531 shares of the company’s stock after acquiring an additional 53,531 shares during the quarter. Simplify Asset Management Inc. owned about 0.11% of Viridian Therapeutics worth $3,222,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of VRDN. Aster Capital Management DIFC Ltd acquired a new stake in Viridian Therapeutics during the third quarter worth $35,000. ANTIPODES PARTNERS Ltd acquired a new stake in Viridian Therapeutics during the fourth quarter worth $36,000. Bessemer Group Inc. boosted its stake in Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after buying an additional 1,886 shares in the last quarter. Larson Financial Group LLC acquired a new stake in Viridian Therapeutics during the third quarter worth $52,000. Finally, US Bancorp DE boosted its stake in Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares in the last quarter.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $17.24 on Monday. The stock has a 50-day simple moving average of $18.85 and a 200 day simple moving average of $26.47. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics, Inc. has a 12-month low of $13.18 and a 12-month high of $34.29. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -5.19 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. During the same period in the previous year, the business posted ($0.87) earnings per share. The firm’s revenue for the quarter was up 95.8% compared to the same quarter last year. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -3.71 earnings per share for the current fiscal year.

Insider Activity

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director directly owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

VRDN has been the topic of a number of recent research reports. Royal Bank Of Canada lifted their price target on shares of Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. The Goldman Sachs Group decreased their price target on shares of Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Evercore set a $26.00 price target on shares of Viridian Therapeutics in a research note on Friday, May 15th. Finally, Wedbush reduced their target price on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.